BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at ...

Following the successful Phase 2 readout of BX211, the Company is planning for a Phase 2/3 trial, pending discussions and feedback from the U.S Food and Drug Administration. "We believe these data ...

The Phase 2 study design was guided in part by experience with numerous compassionate cases using phage therapy for the treatment ... Discussions with the U.S. Food and Drug Administration ...

Pseudo-Xerostomia — Patients feel dry despite normal saliva flow, often due to nerve damage, anxiety or microbiome imbalances ...

It's a 'kill your buddies and eat their food' scenario." Van Tyne said the finding doesn ... one single target for which to design therapeutics such as antibiotics or phage therapy," Van Tyne said.

It's a 'kill your buddies and eat their food' scenario." Van Tyne said the finding doesn ... one single target for which to design therapeutics such as antibiotics or phage therapy," Van Tyne said.

The foods we eat ... ways that we can use phage,” Baker said. “In this case, producing something and releasing it in the gut as kind of a way to have aa long term therapy as opposed to just ...

With antimicrobial resistance rising as one of the world's most pressing health threats, the 8th World Congress on Targeting ...

BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal ...